Article
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
Infectious diseases (London, England) - 1 Jan 2015
Hundemer Gregory L, Sise Meghan E, Wisocky Jessica, Ufere Nneka, Friedman Lawrence S, Corey Kathleen E, Chung Raymond T
Abstract excerpt
Sofosbuvir-based direct-acting antiviral therapy revolutionized the treatment of hepatitis C virus (HCV) infection. However, sofosbuvir use is not approved for patients with severe renal insufficiency (estimated glomerular filtration (eGFR) rate below 30 ml/min) or end-stage renal disease (ESRD) based on concerns raised during premarket animal testing over hepatobiliary and cardiovascular toxicity in this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.